XNAS
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.14 | -0.14 | +0.00% | $226,000 | ➖ Inline | -3.01% | +5.42% | — |
| 2026-03-18 | Q4 2025 | -0.15 | -0.14 | +6.67% | $225,000 | ✅ Beat | +1.20% | -12.02% | +4.81% |
| 2025-11-10 |
| Q3 2025 |
| -0.13 |
| -0.12 |
| +7.69% |
| $217,000 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.14 | -0.13 | +7.14% | $221,000 | ✅ Beat | +2.44% | +4.02% | +33.04% |
| 2025-03-17 | Q4 2024 | -0.15 | -0.16 | -6.67% | $0 | ❌ Miss | -6.77% | -1.92% | -23.47% |
| 2024-08-09 | Q2 2024 | -0.17 | -0.16 | +5.88% | $0 | ✅ Beat | -4.59% | +10.09% | +9.63% |
| 2024-05-10 | Q1 2024 | -0.18 | -0.16 | +11.11% | $0 | ✅ Beat | +9.61% | +44.31% | +7.47% |
| 2024-03-22 | Q4 2023 | — | -0.09 | — | $0 | — | — | — | — |
Showing last 8 quarters.